Publications by authors named "Thomas C Merigan"

26Publications

Role of Physician-Scientists in the Control of Human Immunodeficiency Virus.

Authors:
Thomas C Merigan

J Infect Dis 2018 08;218(suppl_1):S3-S6

George E. and Lucy Becker Professor of Medicine Emeritus, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, California.

View Article and Find Full Text PDF
August 2018

In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis.

Authors:
Barbara A Rath Kaveh Pouran Yousef David K Katzenstein Robert W Shafer Christof Schütte Max von Kleist Thomas C Merigan

PLoS One 2013 17;8(4):e61102. Epub 2013 Apr 17.

Department of Pediatrics, Division of Pneumonology-Immunology, Charité University Medical Center, Berlin, Germany.

View Article and Find Full Text PDF
November 2013

Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.

Authors:
Barbara A Rath Richard A Olshen Jerry Halpern Thomas C Merigan

Viruses 2012 08 7;4(8):1212-34. Epub 2012 Aug 7.

Center for AIDS Research, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.

View Article and Find Full Text PDF
August 2012

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Authors:
Ronald T Mitsuyasu Thomas C Merigan Andrew Carr Jerome A Zack Mark A Winters Cassy Workman Mark Bloch Jacob Lalezari Stephen Becker Lorna Thornton Bisher Akil Homayoon Khanlou Robert Finlayson Robert McFarlane Don E Smith Roger Garsia David Ma Matthew Law John M Murray Christof von Kalle Julie A Ely Sharon M Patino Alison E Knop Philip Wong Alison V Todd Margaret Haughton Caroline Fuery Janet L Macpherson Geoff P Symonds Louise A Evans Susan M Pond David A Cooper

Nat Med 2009 Mar 15;15(3):285-92. Epub 2009 Feb 15.

Center for Clinical AIDS Research and Education, University of California-Los Angeles, 9911 West Pico Boulevard, Suite 980, Los Angeles, California 90035, USA.

View Article and Find Full Text PDF
March 2009

Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.

Authors:
Alison A Motsinger Marylyn D Ritchie Robert W Shafer Gregory K Robbins Gene D Morse Line Labbe Grant R Wilkinson David B Clifford Richard T D'Aquila Victoria A Johnson Richard B Pollard Thomas C Merigan Martin S Hirsch John P Donahue Richard B Kim David W Haas

Pharmacogenet Genomics 2006 Nov;16(11):837-45

Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA.

View Article and Find Full Text PDF
November 2006

Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.

Authors:
Rajesh T Gandhi John Spritzler Ellen Chan David M Asmuth Benigno Rodriguez Thomas C Merigan Martin S Hirsch Robert W Shafer Gregory K Robbins Richard B Pollard

J Acquir Immune Defic Syndr 2006 Aug;42(4):426-34

Massachusetts General Hospital, Boston, MA, USA.

View Article and Find Full Text PDF
August 2006

"Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target.

Authors:
Philip Martin John F Vickrey Gheorghe Proteasa Yurytzy L Jimenez Zdzislaw Wawrzak Mark A Winters Thomas C Merigan Ladislau C Kovari

Structure 2005 Dec;13(12):1887-95

Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.

View Article and Find Full Text PDF
December 2005

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Authors:
David W Haas Laura M Smeaton Robert W Shafer Gregory K Robbins Gene D Morse Line Labbe Grant R Wilkinson David B Clifford Richard T D'Aquila Victor De Gruttola Richard B Pollard Thomas C Merigan Martin S Hirsch Alfred L George John P Donahue Richard B Kim

J Infect Dis 2005 Dec 1;192(11):1931-42. Epub 2005 Nov 1.

Vanderbilt University School of Medicine, Nashville, TN 37203, USA.

View Article and Find Full Text PDF
December 2005

Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.

Authors:
Patrick F Smith Gregory K Robbins Robert W Shafer Hulin Wu Song Yu Martin S Hirsch Thomas C Merigan Jeong-Gun Park Alan Forrest Margaret A Fischl Gene D Morse

Antimicrob Agents Chemother 2005 Aug;49(8):3558-61

Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA.

View Article and Find Full Text PDF
August 2005

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

Authors:
Thomas B Campbell Nancy S Shulman Steven C Johnson Andrew R Zolopa Russell K Young Lane Bushman Courtney V Fletcher E Randall Lanier Thomas C Merigan Daniel R Kuritzkes

Clin Infect Dis 2005 Jul 7;41(2):236-42. Epub 2005 Jun 7.

Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA.

View Article and Find Full Text PDF
July 2005

Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Authors:
Mark A Winters Thomas C Merigan

Antimicrob Agents Chemother 2005 Jul;49(7):2575-82

Division of Infectious Diseases and Geographic Medicine, Stanford University, 300 Pasteur Drive, Room S-146, Stanford, California 94305-5107, USA.

View Article and Find Full Text PDF
July 2005

New two-amino acid insertion near codon 70 of the HIV type 1 protease gene.

Authors:
Mark A Winters Ron M Kagan Peter N R Heseltine Thomas C Merigan

AIDS Res Hum Retroviruses 2005 Apr;21(4):311-3

Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA.

View Article and Find Full Text PDF
April 2005

Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors.

Authors:
Mark A Winters Ron M Kagan Ladislau Kovari Peter N R Heseltine Thomas C Merigan

Antivir Ther 2005 ;10(2):363-6

Center for AIDS Research, Stanford University, Stanford, CA, USA.

View Article and Find Full Text PDF
July 2005

Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays.

Authors:
Nancy S Shulman Jamael Delgado Ronald J Bosch Mark A Winters Elizabeth Johnston Robert W Shafer David A Katzenstein Thomas C Merigan

J Acquir Immune Defic Syndr 2005 May;39(1):78-81

Center for AIDS Research, Division of Infectious Diseases, Stanford University, Stanford, CA 97305, USA.

View Article and Find Full Text PDF
May 2005

Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations.

Authors:
Said H S Al Dhahry Euan M Scrimgeour Abdul Raouf Al Suwaid Mohammed R M Y Al Lawati Hussein S El Khatim Muhannad F Al Kobaisi Thomas C Merigan

AIDS Res Hum Retroviruses 2004 Nov;20(11):1166-72

Department of Microbiology and Immunology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, PC 123 Oman.

View Article and Find Full Text PDF
November 2004

Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.

Authors:
Elizabeth Johnston Mark A Winters Soo-Yon Rhee Thomas C Merigan Celia A Schiffer Robert W Shafer

Antimicrob Agents Chemother 2004 Dec;48(12):4864-8

Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California 94305, USA.

View Article and Find Full Text PDF
December 2004

Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.

Authors:
Ron M Kagan Thomas C Merigan Mark A Winters Peter N R Heseltine

Antivir Ther 2004 Oct;9(5):827-8

View Article and Find Full Text PDF
October 2004

Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.

Authors:
Bradley C Logsdon John F Vickrey Philip Martin Gheorghe Proteasa Jay I Koepke Stanley R Terlecky Zdzislaw Wawrzak Mark A Winters Thomas C Merigan Ladislau C Kovari

J Virol 2004 Mar;78(6):3123-32

Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine, Detroit, Michigan, USA.

View Article and Find Full Text PDF
March 2004

Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.

Authors:
Jeffrey M Jacobson Michael M Lederman John Spritzler Hernan Valdez Pablo Tebas Gail Skowron Rui Wang J Brooks Jackson Lawrence Fox Alan Landay Mark J Gilbert Dorothy O'Neil Lynne Bancroft Lena Al-Harthi Mark A Jacobson Thomas C Merigan Marshall J Glesby

J Infect Dis 2003 Dec 9;188(12):1804-14. Epub 2003 Dec 9.

Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York 10003, USA.

View Article and Find Full Text PDF
December 2003

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:
Robert W Shafer Laura M Smeaton Gregory K Robbins Victor De Gruttola Sally W Snyder Richard T D'Aquila Victoria A Johnson Gene D Morse Mostafa A Nokta Ana I Martinez Barbara M Gripshover Pamposh Kaul Richard Haubrich Mary Swingle S Debra McCarty Stefano Vella Martin S Hirsch Thomas C Merigan

N Engl J Med 2003 Dec;349(24):2304-15

Stanford University Medical Center, Stanford, Calif, USA.

View Article and Find Full Text PDF
December 2003